엑셀세라퓨틱스

373110KOSDAQ

51.3 / 100

Reference Date: 2026-09-08

Financial Score13.5 / 40

News Sentiment20.8 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 15.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Excel Therapeutics focuses on the cell culture media market essential for cell and gene therapy (CGT) development, targeting the rapidly growing cell therapy segment, which is projected to expand from $64 billion in 2024 to $306 billion by 2034. The company is diversifying its business into cultivated meat, cosmetics, artificial blood, and other fields, while advancing domestic media production through continuous R&D.

Number of Employees

65people

Average Salary

66.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.68Industry Average 1.200.0Point

2.2x industry avg (risky)

ROE

-134.41Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

45.55Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲36.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼11.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -157.0% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 83

Positive
엑셀세라퓨틱스 파트너 샹야바이오 대표 “中 재조합 콜라겐스킨부스...
엑셀세라퓨틱스의 중국 재조합 콜라겐스킨부스 출시로 인해 중국 메디컬 뷰티 시장의 트렌드 변화에 긍정적 영향 예상.
Positive
엑셀세라퓨틱스 재조합 콜라겐 총판 계약…매출 500억 도전 [현장+]
엑셀세라퓨틱스의 유전자 재조합 콜라겐 총판 계약으로 매출 증대 기대.
Positive
재조합 콜라겐 독점권 확보…엑셀세라퓨틱스 상한가[특징주]
엑셀세라퓨틱스의 독점 계약 체결로 인해 주가가 상한가를 기록하며 긍정적인 시장 반응을 보임.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,105Won52-week high 2,89552-week low 1,089

1-month return0.0Point

1m -15.91% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14